期刊文献+

直肠癌新辅助治疗的进展 被引量:14

Advance in neoadjuvant therapy for rectal cancer
下载PDF
导出
摘要 直肠癌是常见的恶性肿瘤,随着生活水平提高及饮食习惯原因的改变,直肠癌发病率呈上升趋势。外科手术切除仍是直肠癌最主要的治疗手段,但局部晚期直肠癌患者术后局部复发率高,保肛率低,治疗效果不尽人意。近年,直肠癌新辅助放化疗逐渐受到广泛关注,本文从新辅助放化疗的优点及适应证、新辅助放化疗常用药物、新辅助放疗方案、新辅助放化疗疗效及新辅助治疗后的手术时机选择等方面进行综述。 Rectal cancer is a frequent malignant tumor,as the living standards ′ improving and the reasons for the changes in people's diet,the colorectal cancer incidence is on the rise.Surgical resection is still the most main treat ment for colorectal cancer,but the treatment effect is unsatisfactory in patients with postoperatively locally advanced rectal cancer because of the high local recurrence rate and low anal preservation rate.In recent years,neoadjuvant therapy for colorectal cancer has gained increasingly interest,this essay summarizes neoadjuvant chemoradiation ad vantages and indications,commonly used drugs for neoadjuvant chemoradiation,neoadjuvant radiotherapy plan,neoad juvant chemoradiation curative effect and timing of surgery after neoadjuvant therapy.
出处 《中国医药导报》 CAS 2013年第15期40-42,共3页 China Medical Herald
关键词 直肠癌 新辅助放化疗 进展 Rectal cancer Neoadjuvant chemoradiation Advance
  • 相关文献

参考文献6

二级参考文献75

  • 1Ming Li Jin Gu.Changing patterns of colorectal cancer in China over a period of 20 years[J].World Journal of Gastroenterology,2005,11(30):4685-4688. 被引量:93
  • 2李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:227
  • 3National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:colon cancer.V.2.2011.http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
  • 4National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:rectal cancer.V.2.2011.http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
  • 5Edge SB,Byrd DR,Compton CC,et al.AJCC Cancer Staging Manual.7th ed.New York:Springer,2010.
  • 6Van Custem E,Lang,I,Folprecht G,et al.Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC):The influence of KRAS and BRAF biomarkers on outcome:Updated data from the CRYSTAL trial.ASCOGastrointestinal Cancer Symposium,2010:abstract 281.
  • 7Di Nicolantonio F,Martini M,Molinari F,et al.Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J Clin Oncol,2008,26 (35):5705 -5712.
  • 8Bokmeyer C,Kohne C,Rougier C,et al.Cetuximab with chemotherapy as first-line treatment for metastatic colorectal cancer:Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation analysis.J Clin Oncol,2010,28suppl 15:abstract 3506.
  • 9Saclarides TJ,Smith L,Ko ST,et al.Transanal endoscopic microsurgery.Dis Colon Rectum,1992,35(12):1183-1191.
  • 10Palma P,Freudenberg S,Samel S,et al.Transanal endoscopic microsurgery:indications and results after 100 cases.Colorectal Dis,2004,6(5):350-355.

共引文献102

同被引文献156

引证文献14

二级引证文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部